| abstract |
The present invention relates to the substitution of at least one cysteine residue where each TNFSF ligand or TNF-like ligand mutein monomer promotes the formation of disulfide bonds with cysteine residues on adjacent TNFSF or TNF-like ligand mutein monomers. Or a homomultimer of the TNFSF or TNF-like ligand mutein containing an insertion, eg, a homotrimer. The present invention relates to a method for producing such TNFSF and TNF-like ligand muteins, pharmaceutical compositions containing such muteins, and muteins for cancer immunotherapy, treatment of autoimmune and neurological diseases, and organ transplantation or tissue or organ Characterized by methods used to reduce or eliminate the risk of complications and rejection in repair or regeneration. [Selection figure] None |